

Maria Prendecki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/980409/publications.pdf>

Version: 2024-02-01

42
papers

1,275
citations

471509

17
h-index

414414

32
g-index

48
all docs

48
docs citations

48
times ranked

3036
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of spleen tyrosine kinase decreases donor specific antibody levels in a rat model of sensitization. <i>Scientific Reports</i> , 2022, 12, 3330.	3.3	5
2	Impaired Humoral and Cellular Responses to COVID-19 Vaccine in Heart and Lung Transplant Recipients. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1476-1479.	5.6	4
3	The authors reply:. <i>Kidney International</i> , 2022, 101, 648-649.	5.2	2
4	Glomerulonephritis and autoimmune vasculitis are independent of α 2-macroglobulin but may depend on alternative inflammasome pathways. <i>Journal of Pathology</i> , 2022, 257, 300-313.	4.5	3
5	Comparison of Vaccine Effectiveness Against the Omicron (B.1.1.529) Variant in Hemodialysis Patients. <i>Kidney International Reports</i> , 2022, 7, 1406-1409.	0.8	26
6	Alpha ₁ -Antitrypsin Deficiency: Does Increased Neutrophil Adhesion Contribute to Lung Damage?. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, , .	2.9	0
7	New Therapeutic Targets in Antineutrophil Cytoplasm Antibody-associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2021, 73, 361-370.	5.6	18
8	Informing the Risk of Kidney Transplantation Versus Remaining on the Waitlist in the Coronavirus Disease 2019 Era. <i>Kidney International Reports</i> , 2021, 6, 46-55.	0.8	28
9	SARS-CoV-2 Antibody Point-of-Care Testing in Dialysis and Kidney Transplant Patients With COVID-19. <i>Kidney Medicine</i> , 2021, 3, 54-59.e1.	2.0	5
10	Immunomodulatory Properties of Mesenchymal Stromal Cells Can Vary in Genetically Modified Rats. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1181.	4.1	2
11	Serum chitinase-3-like 1 protein is a useful biomarker to assess disease activity in ANCA-associated vasculitis: an observational study. <i>Arthritis Research and Therapy</i> , 2021, 23, 77.	3.5	8
12	Targeting complement in ANCA-associated vasculitis: insights from ADVOCATE. <i>Nature Reviews Nephrology</i> , 2021, 17, 439-440.	9.6	2
13	Longitudinal proteomic profiling of dialysis patients with COVID-19 reveals markers of severity and predictors of death. <i>ELife</i> , 2021, 10, .	6.0	58
14	Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. <i>Lancet, The</i> , 2021, 397, 1178-1181.	13.7	279
15	Serologic Screening for Coronavirus Disease 2019 in Patients With Glomerular Disease. <i>Kidney International Reports</i> , 2021, 6, 1402-1406.	0.8	3
16	Danger-associated molecular pattern molecules and the receptor for advanced glycation end products enhance ANCA-induced responses. <i>Rheumatology</i> , 2021, , .	1.9	7
17	Single-dose SARS-CoV-2 vaccination efficacy in the elderly. <i>Lancet Infectious Diseases, The</i> , 2021, 21, 1474-1475.	9.1	3
18	Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection. <i>Kidney International</i> , 2021, 99, 1470-1477.	5.2	58

#	ARTICLE	IF	CITATIONS
19	Characterisation of an enhanced preclinical model of experimental MPO-ANCA autoimmune vasculitis. <i>Journal of Pathology</i> , 2021, 255, 107-119.	4.5	4
20	Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1322-1329.	0.9	188
21	ANCA Vasculitis Induction Management During the COVID-19 Pandemic. <i>Kidney International Reports</i> , 2021, 6, 2903-2907.	0.8	8
22	Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis. <i>Kidney International</i> , 2021, 100, 1316-1324.	5.2	26
23	Identification of Patient Characteristics Associated With SARS-CoV-2 Infection and Outcome in Kidney Transplant Patients Using Serological Screening. <i>Transplantation</i> , 2021, 105, 151-157.	1.0	17
24	Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients. <i>Lancet, The</i> , 2021, 398, 1482-1484.	13.7	58
25	COVID-19 vaccination in patients with immunity-mediated kidney disease. <i>Nature Reviews Nephrology</i> , 2021, 17, 790-791.	9.6	4
26	Glucocorticoid-free treatment of severe ANCA-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 739-742.	0.7	6
27	Temporal changes in complement activation in haemodialysis patients with COVID-19 as a predictor of disease progression. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 889-896.	2.9	22
28	Authors' Reply. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2968.2-2968.	6.1	1
29	High Prevalence of Asymptomatic COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1969-1975.	6.1	128
30	Detection of SARS-CoV-2 Antibodies in Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2753-2756.	6.1	34
31	Live Imaging of Monocyte Subsets in Immune Complex-Mediated Glomerulonephritis Reveals Distinct Phenotypes and Effector Functions. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2523-2542.	6.1	16
32	Is There a Role for Plasma Exchange in ANCA-Associated Vasculitis?. <i>Current Treatment Options in Rheumatology</i> , 2020, 6, 313-324.	1.4	4
33	Anti-glomerular basement membrane disease during the COVID-19 pandemic. <i>Kidney International</i> , 2020, 98, 780-781.	5.2	56
34	Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical model. <i>Kidney International</i> , 2020, 97, 1196-1207.	5.2	34
35	In-silico analysis of myeloid cells across the animal kingdom reveals neutrophil evolution by colony-stimulating factors. <i>ELife</i> , 2020, 9, .	6.0	6
36	Plasma exchange in anti-glomerular basement membrane disease. <i>Presse Medicale</i> , 2019, 48, 328-337.	1.9	9

#	ARTICLE	IF	CITATIONS
37	P2X ₇ receptor antagonism ameliorates renal dysfunction in a rat model of sepsis. <i>Physiological Reports</i> , 2018, 6, e13622.	1.7	19
38	Increased Prevalence of Thyroid Disease in Patients with Antineutrophil Cytoplasmic Antibodies-associated Vasculitis. <i>Journal of Rheumatology</i> , 2018, 45, 686-689.	2.0	9
39	Recent advances in understanding of the pathogenesis of ANCA-associated vasculitis. <i>F1000Research</i> , 2018, 7, 1113.	1.6	12
40	Primary IgA nephropathy: current challenges and future prospects. <i>International Journal of Nephrology and Renovascular Disease</i> , 2018, Volume 11, 137-148.	1.8	32
41	Long-term outcome in biopsy-proven acute interstitial nephritis treated with steroids. <i>CKJ: Clinical Kidney Journal</i> , 2017, 10, sfw116.	2.9	37
42	Familial vasculitides: granulomatosis with polyangitis and microscopic polyangitis in two brothers with differing anti-neutrophil cytoplasm antibody specificity. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 429-431.	2.9	7